Artiva Biotherapeutics, Inc.
ARTV
$2.47
$0.020.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -99.25% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.25% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -99.25% | -- | -- | -- | -- |
| SG&A Expenses | 23.67% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.26% | -- | -- | -- | -- |
| Operating Income | -119.37% | -- | -- | -- | -- |
| Income Before Tax | -128.19% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.62% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.62% | -- | -- | -- | -- |
| EBIT | -119.37% | -- | -- | -- | -- |
| EBITDA | -128.32% | -- | -- | -- | -- |
| EPS Basic | -13.43% | -- | -- | -- | -- |
| Normalized Basic EPS | 18.79% | -- | -- | -- | -- |
| EPS Diluted | 34.33% | -- | -- | -- | -- |
| Normalized Diluted EPS | 34.58% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 1,298.47% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 379.16% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |